Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for SVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 -29.75M
March 31, 2026 -33.05M
December 31, 2025 -25.06M
September 30, 2025 -22.53M
June 30, 2025 -26.26M
March 31, 2025 -27.19M
December 31, 2024 -23.28M
September 30, 2024 -22.67M
June 30, 2024 -22.50M
March 31, 2024 -20.64M
December 31, 2023 -15.60M
September 30, 2023 -13.16M
June 30, 2023 -10.27M
March 31, 2023 -12.03M
December 31, 2022 -8.651M
September 30, 2022 -8.162M
June 30, 2022 -9.316M
March 31, 2022 -8.425M
December 31, 2021 -9.363M
September 30, 2021 -8.927M
June 30, 2021 -12.19M
March 31, 2021 -9.597M
December 31, 2020 -12.30M
September 30, 2020 -6.705M
June 30, 2020 -7.752M
Date Value
March 31, 2020 -13.08M
December 31, 2019 -9.946M
September 30, 2019 -11.41M
June 30, 2019 -12.90M
March 31, 2019 -10.86M
December 31, 2018 -10.49M
September 30, 2018 -8.762M
June 30, 2018 -10.35M
March 31, 2018 -9.671M
December 31, 2017 -9.47M
September 30, 2017 -8.249M
June 30, 2017 -7.671M
March 31, 2017 -2.844M
December 31, 2016 -2.19M
September 30, 2016 -2.865M
June 30, 2016 8.013M
March 31, 2016 -11.33M
December 31, 2015 -8.811M
September 30, 2015 -8.256M
June 30, 2015 -8.533M
March 31, 2015 -7.349M
December 31, 2014 -6.015M
September 30, 2014 -5.368M
June 30, 2014 -6.99M
March 31, 2014 -6.272M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 3.573B
Insmed, Inc. -88.83M
United Therapeutics Corp. 310.20M
Vertex Pharmaceuticals, Inc. 1.125B
SELLAS Life Sciences Group, Inc. -7.588M